Johnson & Johnson (J&J) has reported strong financial results for the second quarter of 2026, driven by continued growth across its Innovative Medicine and MedTech businesses. The company also increased its full-year 2026 financial guidance, reflecting confidence in sustained business momentum.
J&J recorded second-quarter sales of $25.3 billion, representing a 6.6% year-over-year increase. Operational sales grew 5.6%, while adjusted operational sales rose 5.7%. The company reported adjusted earnings per share (EPS) of $2.90, exceeding market expectations.
The pharmaceutical giant raised its 2026 adjusted EPS guidance to a range of $11.60–$11.75, up from the previous forecast of $11.45–$11.65. It also increased projected full-year sales to $100.8–$101.4 billion, citing strong demand for its innovative therapies and medical technologies.
Growth in the Innovative Medicine segment was led by continued strong performance of products including Darzalex, Carvykti, Tremfya, and Spravato. While sales of Stelara declined due to biosimilar competition, newer medicines more than offset the impact. The MedTech business also delivered solid growth across multiple product categories.
Commenting on the results, the company said its diversified healthcare portfolio and pipeline continue to support long-term growth despite competitive pressures in certain product lines. J&J remains focused on advancing innovation across oncology, immunology, neuroscience, cardiovascular care, surgery, and medical devices.
The stronger-than-expected quarterly performance reinforces Johnson & Johnson's outlook for 2026 and highlights the company's resilience amid evolving market dynamics.
